Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

Agouron Pharmaceuticals, Inc.’s operations consists of the discovery, development, manufacture, and marketing of therapeutic products engineered to inactivate proteins, which play roles in cancer, AIDS, and other serious diseases. Its product, VIRACEPT®, was a drug for the treatment of HIV infection. Agouron Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Part of Zoetis, Inc., Zoetis Services LLC is a company headquartered in Florham Park, NJ, that discovers, develops, manufactures and sells animal health medicines and vaccines.

Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs. Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines in humans. We think it’s time companion animals reaped the benefits of human medical progress in this field. Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications. To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards. Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.

Genervon is a clinical-stage biopharmaceutical company focused on novel treatments for neurodegenerative diseases and disorders.

Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore.

Part of Ipsen SA, Ipsen Biopharm Ltd. is a company headquartered in Wrexham, UK, that manufactures pharmaceutical products. It was founded in 1982.

GliaMed is a development-stage biopharmaceutical company dedicated to the discovery and development of small molecule drugs which enhance the human body’s innate ability to regenerate. Founded in 2001, the company is focused on the development of compounds termed Regenerative Immunophilin Ligands or RILs. In preclinical models, treatment with RILs has been shown to induce the localized expression of transcription factors characteristic of pluripotent stem cells at the site of acute disease or trauma.

Selective Genetics, Inc. developed gene therapeutics and DNA devices for tissue repair and regeneration. The company was founded by Thomas S. Porter in 1998 and was headquartered Encinitas, CA.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

Delix Therapeutics, Inc. is an American company located in Palo Alto, CA, that develops therapeutics to reduce and alleviate mental suffering. The firm was founded by David E. Olson, Nicholas Haft and Nick Haft. Mark Rus is the current CEO, occupying that position since 2021.\nThe company says this about itself: Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company's compounds are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Many of these molecules are inspired by psychedelic compounds and preserve their efficacy-promoting mechanisms while avoiding their hallucinogenic properties and other safety liabilities. Delix is rapidly advancing these compounds through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. Headquartered in Massachusetts, Delix is building a world-class biotechnology company by combining an experienced team with innovative treatment strategies and scientific rigor to address the significant and growing mental health challenges impacting society.